



Functional Products Used in Alleviation of Oxidative Stress Diseases and Interaction with Human Microbiota 2.0

Guest Editor:

Prof. Dr. Emanuel Vamanu

Faculty of Biotechnology,
University of Agricultural
Sciences and Veterinary
Medicine, 011464 Bucharest,
Romania

Deadline for manuscript
submissions:

closed (30 June 2023)

Message from the Guest Editor

Dear Colleagues,

Functional products (such as probiotics, prebiotics, dietary fibers, plant extracts, etc.) are useful tools in reducing or alleviating the pathological effects of oxidative stress. Moreover, postbiotics and parapostbiotics have emerged as new products for modulating microbiota bioactivity. The development of innovative products is a significant research area that is providing evidence for disease control and the prevention of degenerative pathologies. Thus, for this Special Issue, we aim to publish recent studies presenting possible *in vitro* and *in vivo* evidence of a modulation response through the microbiota pattern. You are also invited to contribute research based on the effect of different drugs that are used in degenerative pathologies and possible interactions with the human microbiota. Side effects are significant in disease management and interactions with associated pathologies. We would like to encourage you to send papers on these and other related aspects relevant to the issue.

- microbiota modulation
- pathology-microbiota
- immunomodulatory effects
- polyphenols
- pro-, pre-, synbiotic nutraceuticals
- postbiotics





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)